Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in Europe ; Partnership with AnGes in Japan Strong

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif. , July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious

First and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies 1   Extended life by an average of 4.3 years in children and young adults with HGPS 2 Now approved for use in 30 European countries, following approval in the